Clinical Trial Update: Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of combination chemotherapy and bevacizumab with or without RO4929097 for metastatic colorectal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Colon
• Adenocarcinoma of the Rectum
• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• RO4929097 (RO4929097)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 2 | Status: WITHDRAWN